Ftse Mib
34.817,06
0,46%
DAX
18.742,22
-0,08%
S&P 500
5.220,11
-0,05%
NASDAQ
16.370,74
0,18%
Bitcoin
62.694,58
2,03%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Regno Unito LSE Aim Immunotech Inc (0A4Y) Aim Immunotech Inc (0A4Y) Notizie

0A4Y

Aim Immunotech (0A4Y)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0A4Y
DataOraFonteTitoloSimboloCompagnia
09/05/202414:50UK RegulatoryAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastLSE:0A4YAim Immunotech Inc
06/05/202414:30UK RegulatoryAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®LSE:0A4YAim Immunotech Inc
29/04/202414:55UK RegulatoryAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerLSE:0A4YAim Immunotech Inc
10/04/202414:21UK RegulatoryAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerLSE:0A4YAim Immunotech Inc
02/04/202413:30UK RegulatoryAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateLSE:0A4YAim Immunotech Inc
26/03/202414:05UK RegulatoryAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastLSE:0A4YAim Immunotech Inc
25/03/202414:05UK RegulatoryAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchLSE:0A4YAim Immunotech Inc
07/03/202414:45UK RegulatoryAIM ImmunoTech Announces Launch of CEO Corner PlatformLSE:0A4YAim Immunotech Inc
29/02/202414:45UK RegulatoryAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateLSE:0A4YAim Immunotech Inc
14/02/202414:55UK RegulatoryAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerLSE:0A4YAim Immunotech Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0A4Y

La tua Cronologia

NASDAQ
CCBLX
All Equity Allocation Po...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network